ASSISTANT PROFESSOR Psychiatry

Specialty Child and Adolescent Psychiatry Clinical Focus Anxiety Attention Deficit Hyperactivity Disorder And Attention Deficit Disorder Conduct Disorder Obsessive-Compulsive Disorder Oppositional Defiant Disorder Training Areas Comentor [COM] Design Technology and Entrepreneurship [DTE] Education MD, Universidad El Bosque - Escuela Medicina Colombiana Residency, Psychiatry Maimonides Medical Center/Conney Island Hosp Fellowship, Child Psychiatry Mount Sinai Hospital Biography Dr. Pedraza works at the ADHD center of excellence and makes part of the team conducting the following clinical trials: 1. Imaging Stimulant and Non-stimulant Treatments for ADHD: A Network- based Approach This five year project examines similarities and differences in neural connectivity before and after treatment with methylphenidate and atomoxetine in youth with ADHD; and also examines the extent to which treatments produce improvement via normalization of function vs. adaptive change. 2. Improving identification of Attention-Deficit/Hyperactivity Disorder (ADHD) and Executive Function in parents of children diagnosed with ADHD using objective measures This study will described the prevalence of ADHD and EF deficits in 50 biological mothers of inner-city youth undergoing treatment for ADHD using state-of-the-art clinical and objective assessment measures. It contributes new information regarding the role of the Quotient™ ADHD system as an adjunct tool for improving the sensitivity and specificity of ADHD diagnosis, and determine the extent to which Quotient™ indices are associated with EF deficits. 3. Measuring and Predicting Response to Atomoxetine and Methylphenidate This two-site study evaluated the relative efficacy, tolerability and palatability of Concerta (methylphenidate) and ATX in the treatment of children and adolescents with ADHD, using a randomized, double blind, cross-over design. 4. Methylphenidate and Atomoxetine in ADHD: fMRI Measures of Mechanisms and Response Functional magnetic resonance imaging (fMRI) was be used to better understand the neurobiological mechanisms of pharmacological treatments for ADHD. 5. Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents with ADHD: an fMRI Study of Brain Activation Pre and Post Treatment This study examines the mechanisms of action of Guanfacine extended release in the treatment of youth with ADHD using a pre/post fMRI design; scans are obtained while performing go/no-go and cued alerting tasks. 6. A Phase 3, Double-blind Placebo-controlled, Multicentre Randomized –withdrawal, Long-term aintenance of Efficacy and Safety Study of Extended-release Guanfacine Hydrochloride in Children and Adolescents Ages 6-17 with Attention-deficit/ Hyperactivity Disorder. This study evaluated the long-term maintenance of efficacy of SPD503 in children and adolescents (6-17) with attention-deficit/hyperactivity disorder (ADHD) who respond to an initial open-label, short-term treatment with SPD503. This was a double-blind, placebo controlled, randomized-withdrawal study design that involved a 7-week open-label dose optimization, followed by 6-week open-label maintenance of the optimized dose. Eligible subjects were randomized to either their assigned dose of SDP503 or matching placebo to evaluate the long-term maintenance of efficacy of the 26-week double-blind randomized withdrawal phase. 7. A Combination of Scheduled Reduced Smoking (SGR) with Varenicline (VN) to Enhance Cessation. J. Erblich. This study aims to provide initial data on the efficacy of combined SGR+VN therapy with regard to smoking cessation, by assessing rates of abstinence and levels of smoking at 2 time points (4 and 12 weeks post quit) following a cessation attempt, in which smokers are randomized (n=48/group) to receive either SGR+VN, SGR+Placebo Drug, Basic Advice+VN, or Basic Advice+Placebo Drug, in a 2 x 2 factorial design. 8. A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose-optimization Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Reference Arm, in Adolescents Aged 13-17 with Attention-deficit/Hyperactivity Disorder (ADHD) 9. A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 Compared with OROS-MPH with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD) 10. Research project on Omega-3 fatty acids as an adjunctive therapy for stimulants in children diagnosed with ADHD. Pedraza JD. Collaborative grant with Glaxo Smith Kline – Maimonides Medical Center 2009. Awards 2012 - POND family foundation award APSARD